Longeveron Inc. cotiza a 2.45 USD y tiene una capitalización bursátil de $8M. En los últimos 12 meses ha facturado $1M con un margen de flujo de caja libre del -1575.5%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors w…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-1.90 | $-1.90 | $-2.20 |
| Estimado | $-1.93 | $-1.90 | $-1.72 | $-3.67 |
| Sorpresa | — | +0.0% | -10.5% | +40.1% |
| Métrica | LGVN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 67.0% | 57.0% | +9.9% |
| Operating Margin | -1942.2% | -38.6% | -1903.6% |
| Net Margin | -1893.6% | -33.6% | -1860.0% |
| FCF Margin | -1575.5% | -13.9% | -1561.6% |
| ROE | -400.1% | -40.4% | -359.7% |
| ROA | -221.3% | -32.0% | -189.3% |
| Current Ratio | 1.33 | 2.84 | -1.51 |
| Debt / Equity | — | 0.28 | — |